Cargando…

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib

While significant progress has been made in the treatment of acute myeloid leukemia (AML), not all patients can be cured. Mutated in about 1/3 of de novo AML, the FLT3 receptor tyrosine kinase is an attractive target for drug development, activating mutations of the FLT3 map to the juxtamembrane dom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uras, Iris Z., Maurer, Barbara, Nebenfuehr, Sofie, Zojer, Markus, Valent, Peter, Sexl, Veronika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321303/ https://www.ncbi.nlm.nih.gov/pubmed/30544932 http://dx.doi.org/10.3390/ijms19123987

Ejemplares similares

CDK6 Inhibition: A Novel Approach in AML Management
por: Uras, Iris Z., et al.
Publicado: (2020)

The Effect of CDK6 Expression on DNA Methylation and DNMT3B Regulation
por: Heller, Gerwin, et al.
Publicado: (2020)

CDK6 Degradation Is Counteracted by p16(INK4A) and p18(INK4C) in AML
por: Schmalzbauer, Belinda S., et al.
Publicado: (2022)

Cdk6: At the interface of Rb and p53
por: Nebenfuehr, Sofie, et al.
Publicado: (2018)

The role of CDK6 in cancer
por: Nebenfuehr, Sofie, et al.
Publicado: (2020)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML
por: Jones, LaQuita, et al.
Publicado: (2021)

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy
por: Saliakoura, Maria, et al.
Publicado: (2023)

A Review of FLT3 Kinase Inhibitors in AML
por: Negotei, Cristina, et al.
Publicado: (2023)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Microenvironmental Hypoxia regulates FLT3 expression and biology in AML
por: Sironi, Silvia, et al.
Publicado: (2015)

Unmasking the vulnerabilities of uninfected children exposed to HIV
por: Ramokolo, Vundli, et al.
Publicado: (2019)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
por: Short, Nicholas J., et al.
Publicado: (2023)

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
por: Popescu, Bogdan, et al.
Publicado: (2023)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Targeting FLT3 mutations in AML: review of current knowledge and evidence
por: Daver, Naval, et al.
Publicado: (2019)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
por: Yamatani, Kotoko, et al.
Publicado: (2022)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
por: Loschi, Michael, et al.
Publicado: (2021)

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
por: Engen, Caroline Benedicte Nitter, et al.
Publicado: (2014)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k3q0msen76vni44ir6ji0l3u2v